human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 2024 ASCO.
human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024. Abstract LBA1000
human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 2024 ASCO.
购书单 电子图书 2024年度榜单 2024年度报告 Hsia Calendar (1924-2024) A Step-by-Step Guide to Destiny Analysis & Feng Shui (平装) 作者: Vincent Koh 出版社: Asiapac Books页数: 296 页定价: 162.0装帧: 平装ISBN: 9789812290779豆瓣评分 目前无人评价 ...
Updated: January 7, 2024byBill Burniece Did you know that many internet marketing experts and gurus turn toPrivate Label Rights(PLR eBooks) for easy done-for-you content for their online businesses? I know this for a fact because many of the top experts in this hot niche market are my ...
截至2024年3月18日,ITT人群中位随访时间18.2个月,仍有119例患者(14%)接受治疗,T-DXd组有89例(20.5%),TPC组有30例(7.2%)。中位既往治疗线数为2线,约90%的患者接受过CDK4/6抑制剂的治疗。 图2 入组患者既往治疗情况 疗效结果...